Abstract: The present disclosure belongs to the technical field of biomedicine and, particularly, relates to a use of an MYOG gene as a target in the preparation of a drug for treating a cardiomyocyte apoptosis-associated cardiovascular disease (CVD). By constructing angiotensin II-induced human induced pluripotent stem cell-differentiated cardiomyocyte apoptosis models in vitro, the present disclosure reveals for the first time the role of the transcription factor MYOG in the inhibition of cardiomyocyte apoptosis and provides a theoretical and scientific basis for drug research and development of cardiomyocyte apoptosis-associated CVDs. MYOG gene becomes a new target for CVD drug research and development.

Abstract: A marker and product for auxiliary diagnosis of valvular heart disease (VHD) is provided. The present disclosure provides for the first time using PLAUR as a biomarker for auxiliary diagnosis of VHD. When the PLAUR is used for auxiliary diagnosis, the diagnostic result can be obtained in only one working day (high detection speed) with sensitivity/accuracy is much higher than the sensitivity/accuracy of NT-ProBNP and hsCRP, and a high-throughput operation is enabled.

Abstract: A use of an MYOG gene as a target in the preparation of a drug for treating a cardiomyocyte apoptosis-associated cardiovascular disease (CVD) is provided. By constructing angiotensin II-induced human induced pluripotent stem cell-differentiated cardiomyocyte apoptosis models in vitro, the present disclosure reveals for the first time the role of the transcription factor MYOG in the inhibition of cardiomyocyte apoptosis and provides a theoretical and scientific basis for drug research and development of cardiomyocyte apoptosis-associated CVDs. Cardiomyocyte apoptosis model becomes a new target for CVD drug research and development.